Cargando…

Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity

Homozygous familial hypercholesterolemia is a rare disease usually caused by LDLR (low-density lipoprotein receptor) mutations. Homozygous familial hypercholesterolemia is characterized by markedly elevated LDL-C (low-density lipoprotein cholesterol) levels and an extremely high risk of premature at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banerjee, Poulabi, Chan, Kuo-Chen, Tarabocchia, Michel, Benito-Vicente, Asier, Alves, Ana C., Uribe, Kepa B., Bourbon, Mafalda, Skiba, Paul J., Pordy, Robert, Gipe, Daniel A., Gaudet, Daniel, Martin, Cesar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Basic Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818983/ https://www.ncbi.nlm.nih.gov/pubmed/31578082 http://dx.doi.org/10.1161/ATVBAHA.119.313051

Ejemplares similares

Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants
por: Benito-Vicente, Asier, et al.
Publicado: (2018)

Treatment of Homozygous Familial Hypercholesterolemia With Evinacumab
por: Jeraj, Natasha, et al.
Publicado: (2021)

MLb-LDLr: A Machine Learning Model for Predicting the Pathogenicity of LDLr Missense Variants
por: Larrea-Sebal, Asier, et al.
Publicado: (2021)

Novel Presentation of Homozygous Familial Hypercholesterolemia With Homozygous Variants in Both LDLR and APOB Genes
por: Derenbecker, Robert, et al.
Publicado: (2019)

Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia
por: Rosenson, Robert S., et al.
Publicado: (2023)

Advantages and Versatility of Fluorescence-Based Methodology to Characterize the Functionality of LDLR and Class Mutation Assignment
por: Etxebarria, Aitor, et al.
Publicado: (2014)

Treatment of Homozygous Familial Hypercholesterolemia With ANGPTL3 Inhibitor, Evinacumab
por: Shamsudeen, Isabel, et al.
Publicado: (2023)

Therapeutic targets of hypercholesterolemia: HMGCR and LDLR
por: Ma, Shizhan, et al.
Publicado: (2019)

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial
por: Rosenson, Robert S., et al.
Publicado: (2023)

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia
por: Pu, Xia, et al.
Publicado: (2021)

High-Throughput Microscopy Characterization of Rare LDLR Variants
por: Graça, Rafael, et al.
Publicado: (2023)

ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report
por: Reeskamp, Laurens F., et al.
Publicado: (2021)

Analysis of the low density lipoprotein receptor gene (LDLR) mutation spectrum in Russian familial hypercholesterolemia
por: Vasilyev, V.B., et al.
Publicado: (2022)

Mutation type classification and pathogenicity assignment of sixteen missense variants located in the EGF-precursor homology domain of the LDLR
por: Galicia-Garcia, Unai, et al.
Publicado: (2020)

Two Novel Disease-Causing Mutations in the LDLR of Familial Hypercholesterolemia
por: Hu, Haochang, et al.
Publicado: (2021)

LDLR gene’s promoter region hypermethylation in patients with familial hypercholesterolemia
por: Zorzo, R. A., et al.
Publicado: (2023)

Management of Familial Hypercholesterolemia with Special Emphasis on Evinacumab
por: Krzemińska, Julia, et al.
Publicado: (2022)

Spontaneous severe hypercholesterolemia and atherosclerosis lesions in rabbits with deficiency of low-density lipoprotein receptor (LDLR) on exon 7
por: Lu, Rui, et al.
Publicado: (2018)

Targeted Disruption of LDLR Causes Hypercholesterolemia and Atherosclerosis in Yucatan Miniature Pigs
por: Davis, Bryan T., et al.
Publicado: (2014)

Endoplasmic reticulum quality control of LDLR variants associated with familial hypercholesterolemia
por: Kizhakkedath, Praseetha, et al.
Publicado: (2019)

Long-Term Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia: Real-World Clinical Experience
por: Stefanutti, Claudia, et al.
Publicado: (2022)

OR24-02 Case Series Of Canadian Patients With Homozygous Familial Hypercholesterolemia Treated With ANGPTL3 Inhibitor Evinacumab
por: Shamsudeen, Isabel, et al.
Publicado: (2023)

Genomic characterization of large rearrangements of the LDLR gene in Czech patients with familial hypercholesterolemia
por: Goldmann, Radan, et al.
Publicado: (2010)

A Japanese case of familial hypercholesterolemia with a novel mutation in the LDLR gene
por: Nagahara, Keiko, et al.
Publicado: (2019)

Exosome-based Ldlr gene therapy for familial hypercholesterolemia in a mouse model
por: Li, Zhelong, et al.
Publicado: (2021)

The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021)

Increased Inflammation in Atherosclerotic Lesions of Diabetic Akita-LDLr (−/−) Mice Compared to Nondiabetic LDLr (−/−) Mice
por: Engelbertsen, Daniel, et al.
Publicado: (2012)

SARS-CoV-2 infection-related deregulation of blood lipids in a patient with -/-LDLR familial homozygous hypercholesterolemia: A case report
por: Bampatsias, Dimitrios, et al.
Publicado: (2023)

A novel indel variant in LDLR responsible for familial hypercholesterolemia in a Chinese family
por: Shu, Hongyan, et al.
Publicado: (2017)

The LDLR c.501C>A is a disease-causing variant in familial hypercholesterolemia
por: Hu, Haochang, et al.
Publicado: (2021)

In vitro assessment of the pathogenicity of the LDLR c.2160delC variant in familial hypercholesterolemia
por: Lin, Shaoyi, et al.
Publicado: (2023)

Screening and verifying the mutations in the LDLR and APOB genes in a Chinese family with familial hypercholesterolemia
por: Lv, Xian, et al.
Publicado: (2023)

Low-Density Lipoprotein Receptor (LDLR) Family Orchestrates Cholesterol Homeostasis
por: Go, Gwang-woong, et al.
Publicado: (2012)

Characterization of low density lipoprotein receptor (LDLR) gene mutations in Albania
por: Diakou, Maria, et al.
Publicado: (2010)

Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA
por: Bjune, Katrine, et al.
Publicado: (2018)

Spectrum of low-density lipoprotein receptor (LDLR) mutations in a cohort of Sri Lankan patients with familial hypercholesterolemia – a preliminary report
por: Paththinige, C. S., et al.
Publicado: (2018)

Characterization of Two Variants at Met 1 of the Human LDLR Gene Encoding the Same Amino Acid but Causing Different Functional Phenotypes
por: Graça, Rafael, et al.
Publicado: (2021)

A genetic variant in the LDLR promoter is responsible for part of the LDL-cholesterol variability in primary hypercholesterolemia
por: De Castro-Orós, Isabel, et al.
Publicado: (2014)

Use of next-generation sequencing to detect LDLR gene copy number variation in familial hypercholesterolemia
por: Iacocca, Michael A., et al.
Publicado: (2017)

Identification of novel variants in the LDLR gene in Russian patients with familial hypercholesterolemia using targeted sequencing
por: Miroshnikova, Valentina V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cgdlh0a060fd7bmlmgtq9mgrob